HomeRGLS • NASDAQ
Follow
Regulus Therapeutics Inc
Previous close
$2.80
Day range
$2.66 - $2.83
Year range
$1.08 - $3.79
Market cap
181.99M USD
Avg Volume
6.34M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 2.54M | 14.33% |
Net income | -8.06M | -18.63% |
Net profit margin | — | — |
Earnings per share | -0.40 | 0.00% |
EBITDA | -8.22M | -19.21% |
Effective tax rate | 0.00% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 23.77M | -39.31% |
Total assets | 30.75M | -34.18% |
Total liabilities | 9.56M | -28.77% |
Total equity | 21.19M | — |
Shares outstanding | 65.47M | — |
Price to book | 2.67 | — |
Return on assets | -60.59% | — |
Return on capital | -73.31% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -8.06M | -18.63% |
Cash from operations | -6.12M | 2.05% |
Cash from investing | 4.93M | -52.88% |
Cash from financing | -873.00K | — |
Net change in cash | -2.07M | -149.03% |
Free cash flow | -3.29M | 14.92% |
About
Regulus Therapeutics Inc. or Regulus is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Wikipedia
Founded
Sep 2007
Website
Employees
30
